RxDoctor Payments Data

Daniel Gerardi, MD

Pulmonary Disease · Hartford, CTNPI 1538167424

Payments from drug & device makers

What this record shows

The money is spread across several categories — speaking fees (58.2%), other and food and beverage — rather than concentrated in one kind of arrangement. 10 manufacturers reported payments, led by Alcon at 34.8% of the total. Among pulmonary disease clinicians in CT with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$155,822in general payments, 2019–2025

Across 162 payments — averaging $961.87 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alcon$54K
  • AstraZeneca$54K
  • GSK$37K
  • Amgen$5K
  • Intuitive Surgical$4K
  • Viiv Healthcare Company$600
  • plus $698 from 4 others

What the payments were for

  • Consulting fees$3450%
  • Speaking & faculty fees$90,66558%
  • Travel & lodging$1,6651%
  • Food & beverage$5,8654%
  • Education$3,0012%
  • Other$54,28235%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$155,822 in reported general payments places this provider in the 95th percentile of 255 pulmonary disease providers in Connecticut.

See all pulmonary disease providers in Connecticut

Medicare billing

Part B allowed, 2024
$118,288
Medicare patients
459
Services billed
1,178

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OfevNintedanib Esylate68$938,536
Trelegy ElliptaFluticasone/Umeclidin/Vilanter556$542,675
Breztri AerosphereBudesonide/Glycopyr/Formoterol194$181,621
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr225$166,111
Fasenra PenBenralizumab21$137,280
Breo ElliptaFluticasone/Vilanterol192$115,919
Ambrisentan24$58,771
Pirfenidone27$46,983
SymbicortBudesonide/Formoterol Fumarate75$28,191
Stiolto RespimatTiotropium Br/Olodaterol Hcl31$23,236
EliquisApixaban14$15,033
Spiriva RespimatTiotropium Bromide14$14,867
Bevespi AerosphereGlycopyrrolate/Formoterol Fum29$13,252
Fluticasone-VilanterolFluticasone/Vilanterol18$9,838
Incruse ElliptaUmeclidinium Bromide16$8,581

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta, Incruse Ellipta$37,223$833,287989 claims
AstraZenecaBreztri Aerosphere, Symbicort, Bevespi Aerosphere$54,264$223,064298 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 255 pulmonary disease providers in Connecticut.

Other pulmonary disease in Hartford

See the full list for Connecticut

Where these figures come from

Is this you, or does something look wrong? →